TNXP: Approval of First New Fibromyalgia Drug in 15 Years Possible in 2025
On April 1, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the fourth quarter and full year 2023 and provided a...
257 Views
Time to execute
With the commencement of enrolment for the pivotal Phase III HONOR study of TNX-102 SL in military-related post-traumatic stress disorder (PTSD),...
123 Views
HONOR study up and running
Tonix Pharmaceuticals has commenced enrolment for the Phase III HONOR study of TNX-102 SL in military-related post-traumatic stress disorder...
59 Views
Breakthrough Therapy Designation in PTSD
Tonix has announced that it has been granted Breakthrough Therapy Designation (BTD) by the FDA as its Phase II AtEase data for TNX-102 SL in...
60 Views
PTSD awareness day and earnings update
Tonix recently held a post-traumatic stress disorder (PTSD) awareness day to highlight the current standards of care, the unmet medical need of the...
30 Views